Viveve Medical (Viveve Medical) Change In Working Capital : $0.77 Mil (TTM As of Sep. 2022)

View and export this data going back to 2016. Start your Free Trial

What is Viveve Medical Change In Working Capital?

Viveve Medical's change in working capital for the quarter that ended in Sep. 2022 was $0.40 Mil.

Viveve Medical's change in working capital for the fiscal year that ended in Dec. 2021 was $4.12 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Viveve Medical Change In Working Capital Historical Data

The historical data trend for Viveve Medical's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viveve Medical Change In Working Capital Chart

Viveve Medical Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Change In Working Capital

Get a 7-Day Free Trial

-1.30

0.40

-2.34

-0.50

4.12

Viveve Medical Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Working Capital	Get a 7-Day Free Trial															1.63	1.53	-0.65	-0.51	0.40

Viveve Medical Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.77 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Viveve Medical Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Viveve Medical's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Viveve Medical (Viveve Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Viveve Medical Inc (OTCPK:VIVE) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

345 Inverness Drive South, Building B, Suite 250, Englewood, CO, USA, 80112

Website

https://www.viveve.com

Viveve Medical Inc designs, develops, manufactures and markets a platform medical technology. Its Cryogen-cooled Monopolar Radiofrequency technology is delivered through a radiofrequency generator, handpiece and treatment tip, called the Viveve System. The Viveve System is for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The Viveve System is indicated for use and being marketed for use in general surgical procedures for electrocoagulation and hemostasis in the United States. It has a business presence in the US, Asia Pacific, Canada, Europe and Middle East and Latin America.

Executives

Presnell Sharon Collins	director	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Wilmot B. Harkey	10 percent owner	C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Daniel Mack	10 percent owner	C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Nantahala Capital Management, Llc	10 percent owner	130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Karen L. Zaderej	director	AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Steven L Basta	director	1875 S GRANT STREET SUITE 110, SAN MATEO CA 94402
Scott Durbin	officer: Chief Financial Officer	PO BOX 376, ANN ARBOR MI 48106
James G. Atkinson	officer: CBO & President	150 COMMERCIAL STREET, SUNNYVALE CA 94086
Patricia Scheller	director, officer: CEO and Director	150 COMMERCIAL STREET, SUNNYVALE CA 94086
Jon M Plexico	director, 10 percent owner	16430 N SCOTTSDALE RD 450, SCOTTSDALE AZ 85254
Stonepine Capital Management, Llc	director, 10 percent owner	919 NW BOND STREET, SUITE 204, BEND OR 97703
Timothy P Lynch	director, 10 percent owner	919 NW BOND STREET, SUITE 204, BEND OR 97703
Daniel Janney	director, 10 percent owner	PO BOX 7414, JACKSON WY 83002